Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Shares Outstanding (Diluted Average) (2022 - 2025)

Historic Shares Outstanding (Diluted Average) for Indivior Pharmaceuticals (INDV) over the last 4 years, with Q3 2025 value amounting to $129.0 million.

  • Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) fell 373.13% to $129.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $129.0 million, marking a year-over-year decrease of 373.13%. This contributed to the annual value of $0.36 for FY2024, which is 526.32% down from last year.
  • Latest data reveals that Indivior Pharmaceuticals reported Shares Outstanding (Diluted Average) of $129.0 million as of Q3 2025, which was down 373.13% from $126.0 million recorded in Q2 2025.
  • In the past 5 years, Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) ranged from a high of $139.0 million in Q4 2022 and a low of $0.31 during Q1 2023
  • In the last 4 years, Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) had a median value of $127.5 million in 2025 and averaged $85.4 million.
  • Per our database at Business Quant, Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) skyrocketed by 4419354828709.68% in 2024 and then plummeted by 875.91% in 2025.
  • Over the past 4 years, Indivior Pharmaceuticals' Shares Outstanding (Diluted Average) (Quarter) stood at $139.0 million in 2022, then fell by 1.44% to $137.0 million in 2023, then dropped by 2.92% to $133.0 million in 2024, then decreased by 3.01% to $129.0 million in 2025.
  • Its last three reported values are $129.0 million in Q3 2025, $126.0 million for Q2 2025, and $125.0 million during Q1 2025.